A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
A gas cylinder exploded in the Spanish coastal town of Velez-Malaga.
The car Mark Ross was travelling in was towed by police, but a kind police officer went out of his way to drive him to be with his family.
French police have fired tear gas and water cannons on protesters defending migrants in the Calais 'jungle' camp.